1 Min Read
March 10 (Reuters) - Invivo Therapeutics Holdings Corp :
* Invivo Therapeutics reports 2016 year-end financial results and business update
* Invivo Therapeutics Holdings Corp qtrly GAAP net loss per diluted share $0.17
* Qtrly adjusted net loss per diluted share 0.21
* Invivo Therapeutics holdings- "ended year with about $33 million in cash, cash equivalents, and marketable securities that we project will fund us into q2 of 2018"
* Expect to submit HDE application for marketing approval of neuro-spinal scaffold by q2 2018
* Plan to initiate first study in cervical SCI in Canada in coming months Source text for Eikon: Further company coverage: